Sri Lanka medicine prices for locally produced drugs supplied to State hospitals are set to rise 12.5%, reopening debate over costs and taxes.
Sri Lanka medicine prices for locally manufactured drugs supplied to State hospitals are set to increase by 12.5%, reopening debate over production costs, public spending and protection for domestic manufacturers.
The Sri Lanka Pharmaceutical Manufacturers’ Association says around 350 locally manufactured medicines are currently purchased for patient treatment in State hospitals. It also says the National Medicines Regulatory Authority had not approved a price revision for these products since 2023.
According to industry representatives, the 12.5% adjustment still falls short of the increase they believe current production costs require.
Manufacturers point to currency depreciation, higher Active Pharmaceutical Ingredient costs, shipping expenses, electricity, fuel and domestic transport as factors increasing the cost of local production. Recent industry commentary has also highlighted taxes on certain pharmaceutical raw materials and research inputs.
Sri Lanka Medicine Prices and the Cost Argument
The manufacturers’ position raises a legitimate question about whether locally produced medicines can remain commercially viable when input costs increase.
However, the equally important question is who should carry that additional burden.
Government hospitals ultimately purchase medicines using public funds. Any price increase therefore affects State health expenditure at a time when the public health system already operates under significant financial pressure.
Critics argue that policymakers should not automatically allow manufacturers to protect margins through higher procurement prices simply because their costs have increased.
Instead, they say authorities should determine the actual production cost of individual medicines through transparent cost audits.
Claims that locally manufactured medicines have historically been purchased at prices above comparable imported products also require medicine-by-medicine evidence. Such claims should not be applied across the entire local pharmaceutical industry without procurement data.
The policy debate should therefore focus on whether each locally manufactured product provides value for money, rather than assuming domestic production is automatically cheaper or more expensive.
Tax Structure Raises a Different Problem
The tax treatment of pharmaceutical inputs has become another major issue.
Industry representatives have argued that some raw materials used in pharmaceutical manufacturing face an 18% VAT, 5% Ports and Airports Development Levy and 2.5% Social Security Contribution Levy, while finished medicine imports may receive more favourable tax treatment.
If that structure raises the cost of domestic production, the Government faces an obvious policy contradiction.
Promoting local manufacturing while taxing essential production inputs more heavily can undermine the very industry the policy seeks to support.
The supplied article also states that 96% of local pharmaceutical production is sold through the Government hospital system and that only around 5% reaches the private market. Current publicly accessible authoritative data reviewed for this rewrite did not independently confirm those exact percentages, so they should not be presented as established national figures without supporting documentation.
A more sustainable solution may therefore involve reviewing taxes on genuine pharmaceutical manufacturing inputs rather than relying primarily on higher procurement prices.
Cost Audits Should Drive Policy
Industry Minister Sunil Handunnetti and other policymakers now face a broader question about how Sri Lanka should support domestic pharmaceutical manufacturing.
Protecting local industry can have strategic advantages, including reducing dependence on imports and strengthening domestic production capacity.
But protection should not mean accepting prices without scrutiny.
Authorities should compare domestic production costs against international procurement prices, product quality, security of supply and the foreign exchange required for imports.
If local manufacturers can deliver safe, effective medicines competitively, the State has a strong reason to support them.
Where imported products offer demonstrably better value without compromising quality or supply security, the Government should also retain the ability to procure internationally.
The central issue should therefore not be local versus imported medicine.
It should be whether Sri Lanka medicine prices reflect transparent costs, proper competition and the best possible use of public money.
The 12.5% increase has exposed that unresolved policy tension.
Public health cannot be treated simply as a commercial market. Yet manufacturers cannot sustainably produce medicines at prices below genuine costs.
The Government’s responsibility is to establish where those genuine costs lie, remove unnecessary structural burdens and ensure that every rupee spent on medicine delivers fair value to patients and taxpayers.
